Protara Therapeutics Files New $300M Shelf Registration, Launches $100M At-The-Market Offering
TARA sits 88% above its 52-week low of $2.77.
Summary
Protara Therapeutics filed a new shelf registration for up to $300 million in securities, including a $100 million At-The-Market (ATM) common stock offering, to fund its clinical development programs.
Key Events · Financing and Capital Events · TARA
-
New Shelf Registration Filed
Protara Therapeutics filed a new universal shelf registration statement for up to $300 million in common stock, preferred stock, debt securities, and warrants. This replaces a prior S-3 and includes $110.9 million in unsold securities from the previous registration, totaling over $410 million in potential offering capacity.
-
$100M At-The-Market (ATM) Offering Launched
The company established a new ATM program to sell up to $100 million of common stock through TD Cowen. This represents approximately 34.9% of the company's current market capitalization.
-
Purpose of Funds
Proceeds are earmarked for the clinical development of TARA-002 (for NMIBC and LMs) and IV Choline Chloride, other potential clinical programs, working capital, and general corporate purposes.
-
Significant Potential Dilution
The ATM program alone could result in approximately 34.86% dilution based on current outstanding shares, with the full shelf capacity representing over 140% of the current market cap. This follows a recent shareholder approval for an increase in authorized common stock.
Analysis · TARA · Life Sciences
Protara Therapeutics has filed a new universal shelf registration statement, allowing it to offer up to $300 million in various securities, including common stock, preferred stock, debt, and warrants. This new registration replaces a prior S-3 and carries forward $110.9 million in unsold securities, bringing the total potential offering capacity to over $410 million. Concurrently, the company established a new At-The-Market (ATM) equity program to sell up to $100 million of common stock through TD Cowen. This substantial capital raise, representing a significant portion of the company's market capitalization, is intended to fund ongoing clinical development for its TARA-002 and IV Choline Chloride programs, as well as general corporate purposes. While necessary for a clinical-stage biotech to extend its cash runway, the large potential dilution could create an overhang on the stock.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARA was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $286.3M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.